Navigation Links
Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloitte's 2007 Washington State Technology 'Fast 50' for 4th Time in Past 6 Years
Date:9/28/2007

instruments used in Urology, Acute Care, Primary Care, and Extended Care. BladderScan(R) helps diagnose urinary-related problems such as enlarged prostate (BPH) and overactive bladder (OAB), and is clinically proven to prevent unnecessary urinary catheterizations and reduce rates of urinary tract infection. The company also manufactures and markets the innovative GlideScope(R) video laryngoscope (GVL(R)). GlideScope(R) provides a consistently clear view of the airway, enabling quick intubation, and offers significant benefits to Anesthesiology, Emergency, Critical Care, EMS professionals. GlideScope(R) is also being used by the military in both Afghanistan and Iraq.

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2002 and $5,000,000 in 2006, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.

Winners of the 16 regional Technology Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks North America's top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Technology Fast 50 or Technology Fast 500 programs, visit http://www.fast500.com.

About Verathon Inc.

Verathon(R), formerly Diagnostic Ultrasound Corp., designs and manufactures reliable, state-of-the-art medical devices and services that offer a meaningful improvement in patient care to the health care community. The company's noninvasive BladderScan(R) instrument is the standard of care for bladder volume measu
'/>"/>

SOURCE Verathon Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Researchers identify the early makers of Neonatal Sepsis
2. New pacemaker reduces risk of heart failure
3. Epilepsy Patients Could Benefit From Pacemakers
4. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
5. Stem Cells Could Replace Electronic Pacemakers
6. Lawmakers alerted on new tobacco control policies by research team
7. Novel Biological Pacemaker Under Construction for Weak Hearts
8. Chocolate makers to be health wise and urge consumers to be too!
9. Drug Makers Banned From Providing Gifts To Doctors
10. Knowing spread of AIDS: a crime; urges Chinese lawmaker.
11. Lawsuit Against Sunscreen Makers For False Claims of Protection Against Skin Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 1Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 2Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2